Graft Versus Host Disease (GVHD)
BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease
Original Publication Date
Article Source
External Web Content
Key Points BCL2 overexpression in T cells is related to a lower risk of GVHD. BCL2 inhibitors should be used with caution after allogeneic hematopoietic stem cell transplantation. Abstract Graft-versus-host disease (GVHD) is a leading cause of morbidity and mortality after…
2026 New Brunswick Patient and Family Conference
CONFERENCE LOCATION:
Heldrich Hotel
10 Livingston Avenue
New Brunswick, NJ 08901
Parking:
Complimentary hotel valet parking
Cord Blood Transplant
Topic(s)
Bone Marrow Transplant
Presenter(s)
Filippo Milano, MD, PhD
During this webinar, Dr. Filippo Milano will discuss cord blood transplant and its role in treating blood cancers and hematological disorders. He will discuss the unique benefits of cord blood as a stem cell source, recent advances in transplantation techniques, and strategies to…
A randomized, multicenter phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide
Original Publication Date
Article Source
External Web Content
Highlights While post-transplantation cyclophosphamide (PTCy) was compared to other graft-versus-host-disease (GVHD) prophylaxis regimens in randomized trials, the optimal combination of immunosuppressive agents with PTCy was not previously established, but combination of…
The role of HLA transcription in unrelated hematopoietic cell transplantation
Original Publication Date
Article Source
External Web Content
Abstract Expression levels of HLA are associated with susceptibility to various diseases and outcomes after allogeneic hematopoietic cell transplantation (HCT). However, there has been no comprehensive analysis of the effect of the expression levels of the HLA-A, -B, -C, and…
Transplant Associated Thrombotic Microangiopathy (TA-TMA)
Topic(s)
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Bone Marrow Transplant
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric Bone Marrow Failure Diseases
Related Bone Marrow Failure Diseases and Malignancies
Presenter(s)
Sumithira Vasu, MD
During this webinar, Dr. Sumithira Vasu will discuss the diagnosis, treatment, and impact of transplant-associated thrombotic microangiopathy (TA-TMA). After the presentation, there will be a question-and-answer session. Questions can be submitted in advance to help@aamds.org.
Is a Transplant Right for me? - Making Decisions
Topic(s)
Bone Marrow Transplant
During this webinar, Dr. Joseph Pidala will discuss how patients and the medical team work together to make transplant decisions. After the presentation, there will be a panel Q & A session. Questions can be submitted in advance to help@aamds.org.
Good job, Good health, Good life. Then: Aplastic Anemia, Followed by PNH. Daniel’s Story
In 2009, Daniel had a good job in accounting in Sydney, Australia. He had a structured, organized, healthy lifestyle. He had a devoted partner (whom he later married) and was studying for the Chartered Accountancy qualification. He rode his bike to work and played soccer. He was planning a good life ahead.
One day at the office, the receptionist pinched his arm. The next day, he saw a huge welt in the same spot. Because a colleague urged him to get it checked out, he did.
Health-Related Quality of Life, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium
Presenter(s)
Namrata Chandhok, MD
Thomas LeBlanc, MD, MA
Fabio Efficace, PhD
Alison R. Kavanaugh
Pamela C. Egan, MD
Wil L. Santivasi, MD
The session was recorded at the AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium, Co-Chairs Namrata Chandhok, MD, and Thomas LeBlanc, MD, MA Topics and speakers included: How can we measure quality of life in MDS, to inform interventions? - Fabio Efficace, PhD…